TRU vs. MXCT, TRMR, HUR, ACRL, TUNG, ADT, ULS, STAF, FCCN, and FA
Should you be buying TruFin stock or one of its competitors? The main competitors of TruFin include MaxCyte (MXCT), Tremor International (TRMR), Hurricane Energy (HUR), Accrol Group (ACRL), Tungsten (TUNG), AdEPT Technology Group (ADT), ULS Technology (ULS), Staffline Group (STAF), French Connection Group (FCCN), and FireAngel Safety Technology Group (FA). These companies are all part of the "business services" industry.
TruFin vs.
TruFin (LON:TRU) and MaxCyte (LON:MXCT) are both small-cap financial services companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
MaxCyte received 114 more outperform votes than TruFin when rated by MarketBeat users. However, 70.91% of users gave TruFin an outperform vote while only 68.92% of users gave MaxCyte an outperform vote.
TruFin has a net margin of 7.29% compared to MaxCyte's net margin of -78.37%. TruFin's return on equity of 6.83% beat MaxCyte's return on equity.
In the previous week, TruFin and TruFin both had 1 articles in the media. TruFin's average media sentiment score of 1.32 beat MaxCyte's score of -0.91 indicating that TruFin is being referred to more favorably in the media.
61.6% of TruFin shares are owned by institutional investors. Comparatively, 70.5% of MaxCyte shares are owned by institutional investors. 23.1% of TruFin shares are owned by insiders. Comparatively, 1.5% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
TruFin has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.
TruFin has higher earnings, but lower revenue than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than TruFin, indicating that it is currently the more affordable of the two stocks.
Summary
TruFin beats MaxCyte on 9 of the 14 factors compared between the two stocks.
Get TruFin News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (LON:TRU) was last updated on 3/31/2025 by MarketBeat.com Staff
Buy TRU Stock Free TRU Stock Alerts